Home › Trial NCT07530094
Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
- Trial IDNCT07530094
- StatusRecruiting
- PhasePhase 2
- Study typeInterventional
- SponsorNing Jiang, M.D./Ph.D.
- Enrollment98
- Start date2025-12-01
- ConditionsLocally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.